Article
A Visually Interpretable Histopathology-Based Immune Model Predicts T-effector Biology and Response to Immune checkpoint inhibition in Clear Cell Renal Cell Carcinoma Clinical Trial and Contemporary Real-World Datasets
2026-06-25
Abstract excerpt
Immune checkpoint inhibitors (ICI) are central to the treatment of metastatic clear cell renal cell carcinoma (ccRCC), yet only a subset of patients derive durable benefit, and clinically deployable predictive biomarkers remain an unmet need. RNA-based T-effector signatures capture cytotoxic immune biology and have been associated with ICI response in clinical trial cohorts; however, their clinical implementation...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- ac6ee795-cc69-58b1-8144-8c7013bb89e5
- DOI
- 10.64898/2026.06.21.733614
